Regeneron Pharmaceuticals Continue Higher Following a Mid-Day Report from Deutsche Bank

By: via Benzinga
Deutsche Bank released a mid-day report Tuesday on Regeneron Pharmaceuticals (NASDAQ: REGN ) in which the firm maintained its Buy rating and raised the price target from $375 to $410. In evaluating Regeneron, Deutsche Bank's Robyn Karnauskas noted the key take away from Regeneron's fourth quarter 2013 as being, "The
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.